Cargando…
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
BACKGROUND: Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. METHODS: We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotens...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003738/ https://www.ncbi.nlm.nih.gov/pubmed/36910697 http://dx.doi.org/10.1093/ofid/ofad073 |
_version_ | 1784904675113304064 |
---|---|
author | Mwimanzi, Francis Lapointe, Hope R Cheung, Peter K Sang, Yurou Yaseen, Fatima Kalikawe, Rebecca Datwani, Sneha Burns, Laura Young, Landon Leung, Victor Ennis, Siobhan Brumme, Chanson J Montaner, Julio S G Dong, Winnie Prystajecky, Natalie Lowe, Christopher F DeMarco, Mari L Holmes, Daniel T Simons, Janet Niikura, Masahiro Romney, Marc G Brumme, Zabrina L Brockman, Mark A |
author_facet | Mwimanzi, Francis Lapointe, Hope R Cheung, Peter K Sang, Yurou Yaseen, Fatima Kalikawe, Rebecca Datwani, Sneha Burns, Laura Young, Landon Leung, Victor Ennis, Siobhan Brumme, Chanson J Montaner, Julio S G Dong, Winnie Prystajecky, Natalie Lowe, Christopher F DeMarco, Mari L Holmes, Daniel T Simons, Janet Niikura, Masahiro Romney, Marc G Brumme, Zabrina L Brockman, Mark A |
author_sort | Mwimanzi, Francis |
collection | PubMed |
description | BACKGROUND: Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. METHODS: We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24–98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time. RESULTS: Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk. CONCLUSIONS: Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses. |
format | Online Article Text |
id | pubmed-10003738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-100037382023-03-11 Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine Mwimanzi, Francis Lapointe, Hope R Cheung, Peter K Sang, Yurou Yaseen, Fatima Kalikawe, Rebecca Datwani, Sneha Burns, Laura Young, Landon Leung, Victor Ennis, Siobhan Brumme, Chanson J Montaner, Julio S G Dong, Winnie Prystajecky, Natalie Lowe, Christopher F DeMarco, Mari L Holmes, Daniel T Simons, Janet Niikura, Masahiro Romney, Marc G Brumme, Zabrina L Brockman, Mark A Open Forum Infect Dis Major Article BACKGROUND: Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. METHODS: We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24–98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time. RESULTS: Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk. CONCLUSIONS: Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses. Oxford University Press 2023-02-09 /pmc/articles/PMC10003738/ /pubmed/36910697 http://dx.doi.org/10.1093/ofid/ofad073 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Mwimanzi, Francis Lapointe, Hope R Cheung, Peter K Sang, Yurou Yaseen, Fatima Kalikawe, Rebecca Datwani, Sneha Burns, Laura Young, Landon Leung, Victor Ennis, Siobhan Brumme, Chanson J Montaner, Julio S G Dong, Winnie Prystajecky, Natalie Lowe, Christopher F DeMarco, Mari L Holmes, Daniel T Simons, Janet Niikura, Masahiro Romney, Marc G Brumme, Zabrina L Brockman, Mark A Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine |
title | Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine |
title_full | Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine |
title_fullStr | Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine |
title_full_unstemmed | Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine |
title_short | Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine |
title_sort | impact of age and severe acute respiratory syndrome coronavirus 2 breakthrough infection on humoral immune responses after three doses of coronavirus disease 2019 mrna vaccine |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003738/ https://www.ncbi.nlm.nih.gov/pubmed/36910697 http://dx.doi.org/10.1093/ofid/ofad073 |
work_keys_str_mv | AT mwimanzifrancis impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT lapointehoper impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT cheungpeterk impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT sangyurou impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT yaseenfatima impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT kalikawerebecca impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT datwanisneha impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT burnslaura impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT younglandon impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT leungvictor impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT ennissiobhan impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT brummechansonj impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT montanerjuliosg impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT dongwinnie impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT prystajeckynatalie impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT lowechristopherf impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT demarcomaril impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT holmesdanielt impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT simonsjanet impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT niikuramasahiro impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT romneymarcg impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT brummezabrinal impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine AT brockmanmarka impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine |